P=N/A, N=73, Completed, Nantes University Hospital | Active, not recruiting --> Completed | N=110 --> 73

The patient received combination chemotherapy with gemcitabine, carboplatin, and bevacizumab, achieving a near-complete metabolic response. Immunohistochemistry plays a crucial role in identifying the primary tumor origin. Management requires a staged approach with emergency surgical intervention followed by multidisciplinary oncological treatment for optimal outcomes.

It also considerably reduced NF-kB p65 and inflammatory markers in comparison with cisplatin alone. Our study demonstrated that rhIGFBP-3 enhanced cisplatin efficacy by promoting apoptosis and attenuating inflammation, highlighting its potential as both a cisplatin adjuvant and a monotherapy in HeLa cells.

This phase II study (ChiCTR2300077718) aimed to assess the efficacy and safety of balloon-occluded HAIC (bHAIC) based on the FOLFOX (oxaliplatin plus fluorouracil and leucovorin) regimen (bHAIC-FO) in unresectable HCC. bHAIC-FO demonstrates encouraging efficacy and acceptable safety profiles in unresectable HCC treatment, particularly in treatment-naive patients. www.chictr.org.cn, identifier ChiCTR2300077718.

Importantly, irofulven and ferroptosis inducer RSL3 exerted significant synergistic effects on HNSCC in vitro and in vivo. Altogether, this study offers a potential strategy for developing a combination therapy for targeting ferroptosis in the treatment of HNSCC.

Collectively, our findings establish the H3K18la-HNRNPF-Parkin axis as a previously unrecognized signaling cascade that bridges epigenetic reprogramming and mitochondrial quality control in chemoresistance. Targeting this axis, particularly the HNRNPF-Parkin interaction or mitophagy activation, presents a novel therapeutic strategy to overcome cisplatin resistance in BCa.

This retrospective study investigated the relationship between baseline SLC28A3 expression levels, quantified via reverse-transcriptase polymerase chain reaction (qRT-PCR), and the incidence of AIHA in a cohort of CLL patients receiving fludarabine and cyclophosphamide (FC) therapy. These findings suggest that diminished baseline SLC28A3 expression may correlate with an elevated risk of fludarabine-emergent AIHA in CLL patients. Further validation through larger, prospective cohorts is essential to confirm the predictive utility of SLC28A3 expression for optimizing fludarabine-based therapeutic strategies.

In conclusion, LINC00312 increased PAX5 mRNA stability by recruiting PABPC1, which promoted LPLUNC1 transcription to regulate sensitivity of NPC to gemcitabine. Meanwhile, PAX5 in turn transcriptionally activated LINC00312 to form a feedback axis, which further increased gemcitabine sensitivity.

In conclusion, this study identifies a previously uncharacterized HIF-1α/circSPECC1/IGF2BP2/PGK1 axis that drives metabolic adaptation and TMZ resistance in GBM. Targeting this axis overcomes acquired chemoresistance, positioning circSPECC1 as both a prognostic biomarker and a therapeutic vulnerability in hypoxic GBM niches.

Here, we found that multiple lipid metabolism processes are aberrantly activated in Ara-C resistant AML cells, accompanied by upregulation of JAK-STAT3 signaling and key lipid metabolic regulators, notably SREBP1 and CPT2...Our findings highlight the critical role of STAT3-driven lipid metabolism reprogramming in chemoresistance. Furthermore, W1307 emerges as a promising therapeutic candidate to overcome chemoresistance in leukemia treatment.

Scanning electron microscopy, immunofluorescence, Western Blot, and other molecular functional assays show that the ERRα/LDHA axis drives lactate accumulation, downregulates inflammasome-related proteins (NLRP3, caspase-1, GSDMD and GSDMD-N), thereby suppressing pyroptosis and promoting resistance to cisplatin, carboplatin, and paclitaxel in ovarian cancer cells. Created in BioRender. Ren, Y. (2025) https://BioRender.com/qeh0dw8.

P4, N=90, Completed, Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh | Recruiting --> Completed | Trial completion date: Dec 2024 --> Jan 2026 | Trial primary completion date: Jun 2024 --> Jan 2026